FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:526-527 August 3, 2006 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kaushansky, K. PubMed Citation

To the Editor: Kaushansky (May 11 issue)¹ reports that "more recent studies indicate that patients treated for breast cancer with cyclophosphamide and doxorubicin may have an increased risk of myelodysplasia or acute myelogenous leukemia if they have also received G-CSF [granulocyte colony-stimulating factor]." Among the studies cited, Smith et al.² found a positive association between the use and dose of G-CSF and the risk of secondary acute leukemia in patients receiving standard doses of anthracycline and dose-intensified cyclophosphamide (cumulative incidence of myelodysplasia or acute myelogenous leukemia at five years, 1.01 percent), but distinguishing the contribution of intensified therapy from that . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.